Biocon buys Viatris biosimilars unit for $3.34 bln; Infosys launches 'Metaverse Foundry'; Prime closes Fund IV at $120 mln

3568 Listen ins

Biocon Biologics has struck a $3.335 billion cash-and-stock deal with US pharmaceuticals company Viatris to acquire its global biosimilars business including rights in the partnered in-licensed portfolio. Infosys has launched a 'metaverse foundry' to fast-track its customers' adoption of the online environment. And Prime Venture Partners, a Bangalore VC firm focused on early-stage startups has closed its latest fund at $120 million